A vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Agilent Technologies exhibits strong fundamental health with a Piotroski F-Score of 8/9, indicating robust accounting strength, and solid profitability metrics including an ROE of 20.62% and operating margin of 26.38%. The company is growing revenue and earnings at double-digit rates, supported by consistent earnings beat rates and strong cash flow generation, though key financial data like Altman Z-Score and cash/debt figures are missing. However, the stock trades at a premium valuation (P/E of 30.28 vs sector average of 215 but with much lower growth than peers), and insider selling activity raises caution. While analysts are bullish with a $169.67 target price, the technical trend is bearish and recent price performance has been weak over the past year despite a short-term rebound.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
A vs LLY: Head-to-Head Comparison
This page compares Agilent Technologies, Inc. (A) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.